Shares of Omnicell, Inc. (NASDAQ:OMCL) have been assigned an average recommendation of “Buy” from the eleven analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $70.88.
OMCL has been the topic of a number of research reports. Benchmark boosted their target price on shares of Omnicell from $66.00 to $79.00 and gave the stock a “buy” rating in a research report on Friday, October 5th. BidaskClub lowered shares of Omnicell from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 4th. Craig Hallum boosted their target price on shares of Omnicell from $65.00 to $80.00 and gave the stock a “buy” rating in a research report on Monday, September 17th. Zacks Investment Research raised shares of Omnicell from a “sell” rating to a “hold” rating in a research report on Monday, August 13th. Finally, MED boosted their target price on shares of Omnicell from $59.00 to $71.00 and gave the stock an “in-line” rating in a research report on Monday, October 22nd.
In related news, EVP Dan S. Johnston sold 6,250 shares of the business’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $63.47, for a total transaction of $396,687.50. Following the transaction, the executive vice president now owns 35,996 shares of the company’s stock, valued at $2,284,666.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James T. Judson sold 2,443 shares of the business’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $70.67, for a total transaction of $172,646.81. Following the transaction, the director now directly owns 24,952 shares in the company, valued at approximately $1,763,357.84. The disclosure for this sale can be found here. Insiders have sold 24,267 shares of company stock worth $1,653,616 in the last ninety days. 3.71% of the stock is currently owned by insiders.
Shares of Omnicell stock traded up $1.30 on Monday, reaching $77.23. The stock had a trading volume of 378,471 shares, compared to its average volume of 340,498. The company has a current ratio of 1.78, a quick ratio of 1.32 and a debt-to-equity ratio of 0.27. Omnicell has a fifty-two week low of $39.75 and a fifty-two week high of $77.75. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of 429.06, a PEG ratio of 4.53 and a beta of 0.98.
Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, October 25th. The company reported $0.49 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.40 by $0.09. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. The business had revenue of $204.27 million during the quarter, compared to analysts’ expectations of $203.48 million. As a group, research analysts predict that Omnicell will post 1.42 earnings per share for the current year.
Omnicell Company Profile
Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.
Featured Story: Google Finance
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.